Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Eli Lilly to Enhance Presence in GP Market: Mr Crenshaw
April 2, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
April 2, 2007
-
ARCHIVE Eisai Embarks on Antibody Pharmaceuticals Business by Acquiring Morphotek
April 2, 2007
-
ARCHIVE JMA Symposium on Stimulation of Clinical Trials
April 2, 2007
-
ARCHIVE Suzuken to Place Top Priority on Customer Satisfaction, Promote M&As: New President Ota
April 2, 2007
-
ARCHIVE ANTCliPh Completes PK Study in Patients with Renal Disorders
April 2, 2007
-
ARCHIVE Market for Ethical Drugs in Japan Fell 0.6% in 2006: IMS
April 2, 2007
-
ARCHIVE Clinical Research on Regenerative Medicine for Spinal Injuries to Start
April 2, 2007
-
ARCHIVE 1st Gov't-Industry Dialogue Held on Distribution Issues
April 2, 2007
-
ARCHIVE R&D NEWS IN BRIEF
April 2, 2007
-
ARCHIVE Takeda Acquires Paradigm of the UK
March 26, 2007
-
ARCHIVE Operating Profit Rate for 28 FJPWA-Affiliated OTC Drug Wholesalers Up 0.41 Points
March 26, 2007
-
ARCHIVE Nippon Chemiphar to Enter Chinese Market, Expand Generic Business
March 26, 2007
-
ARCHIVE Spread of Use of Steroids Reduces Asthma Deaths: GSK Seminar
March 26, 2007
-
ARCHIVE SymBio Licenses AB-1001 from Abeille
March 26, 2007
-
ARCHIVE Multiple Drug-Resistant P. Aeruginosa Detected in 85.8% of Core Hospitals
March 26, 2007
-
ARCHIVE Wholesalers Should Ally with Dispensing Pharmacies: Mr Kimura
March 26, 2007
-
ARCHIVE Number of Local Gov't Hospitals Drops below 1,000: MIC White Paper
March 26, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 26, 2007
-
COMMENTARY Japanese Pharma Companies' Licensing Policy: 1 (1) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…